88 related articles for article (PubMed ID: 28031530)
1. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.
Rosso V; Petiti J; Bracco E; Pedrola R; Carnuccio F; Signorino E; Carturan S; Calabrese C; Bot-Sartor G; Ronconi M; Serra A; Saglio G; Frassoni F; Cilloni D
Oncotarget; 2017 Jan; 8(4):6399-6405. PubMed ID: 28031530
[TBL] [Abstract][Full Text] [Related]
2. Leukemic conversion involving
Gurban P; Mambet C; Botezatu A; Necula LG; Neagu AI; Matei L; Pitica IM; Nedeianu S; Chivu-Economescu M; Bleotu C; Ataman M; Mocanu G; Saguna C; Pavel AG; Stambouli D; Sepulchre E; Anton G; Diaconu CC; Constantinescu SN
Front Oncol; 2023; 13():1266996. PubMed ID: 37841434
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Kucine N
Curr Hematol Malig Rep; 2020 Apr; 15(2):141-148. PubMed ID: 32172359
[TBL] [Abstract][Full Text] [Related]
4. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
5. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
Tang Q; Zhang XW; Xia L; Jiang NK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
[TBL] [Abstract][Full Text] [Related]
6. Conventional cytogenetics for myeloid neoplasms in the era of next-generation-sequencing.
Kuo FC; Steensma DP; Dal Cin P
Am J Hematol; 2017 Mar; 92(3):227-229. PubMed ID: 28054397
[No Abstract] [Full Text] [Related]
7. Kinase signaling and targeted therapy for primary myelofibrosis.
Yang Q; Crispino JD; Wen QJ
Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.
Sala Torra O; Othus M; Williamson DW; Wood B; Kirsch I; Robins H; Beppu L; O'Donnell MR; Forman SJ; Appelbaum FR; Radich JP
Biol Blood Marrow Transplant; 2017 Apr; 23(4):691-696. PubMed ID: 28062215
[TBL] [Abstract][Full Text] [Related]
9. Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm.
Nguyen TK; Morse SJ; Fleischman AG
J Vis Exp; 2016 Dec; (118):. PubMed ID: 28060252
[TBL] [Abstract][Full Text] [Related]
10. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
12. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
Arun AK; Senthamizhselvi A; Mani S; Vinodhini K; Janet NB; Lakshmi KM; Abraham A; George B; Srivastava A; Srivastava VM; Mathews V; Balasubramanian P
Int J Lab Hematol; 2017 Jun; 39(3):235-242. PubMed ID: 28035733
[TBL] [Abstract][Full Text] [Related]
13. Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.
Fischer M; Schnetzke U; Spies-Weisshart B; Walther M; Fleischmann M; Hilgendorf I; Hochhaus A; Scholl S
Haematologica; 2017 Apr; 102(4):e129-e131. PubMed ID: 28034991
[No Abstract] [Full Text] [Related]
14. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.
Chang YC; Lin HC; Chiang YH; Chen CG; Huang L; Wang WT; Cheng CC; Lin J; Chang YF; Chang MC; Hsieh RK; Chen SJ; Lim KH; Kuo YY
Med Oncol; 2017 May; 34(5):83. PubMed ID: 28389907
[TBL] [Abstract][Full Text] [Related]
15. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T; Tefferi A; Vannucchi AM; Passamonti F; Silver RT; Hoffman R; Verstovsek S; Mesa R; Kiladjian JJ; Hehlmann R; Reiter A; Cervantes F; Harrison C; Mc Mullin MF; Hasselbalch HC; Koschmieder S; Marchetti M; Bacigalupo A; Finazzi G; Kroeger N; Griesshammer M; Birgegard G; Barosi G
Leukemia; 2018 May; 32(5):1057-1069. PubMed ID: 29515238
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with
Socoro-Yuste N; Čokić VP; Mondet J; Plo I; Mossuz P
Mol Cancer Res; 2017 Jul; 15(7):852-861. PubMed ID: 28314843
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
19. A novel molecular assay using hybridisation probes and melt curve analysis for
Keaney T; O'Connor L; Krawczyk J; Abdelrahman MA; Hayat AH; Murray M; O'Dwyer M; Percy M; Langabeer S; Haslam K; Glynn B; Mullen C; Keady E; Lahiff S; Smith TJ
J Clin Pathol; 2017 Aug; 70(8):662-668. PubMed ID: 28143941
[TBL] [Abstract][Full Text] [Related]
20. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]